PDF
ePub
Citation
Print
Abstract
Purpose
We wanted to evaluate the accuracy of sentinel lymph node biopsy (SLNB) in patients with clinically negative lymph node after neoadjuvant chemotherapy.
Methods
Fifty-nine women underwent 4 cycles of neoadjuvant chemotherapy with epirubicin (75 mg/m²) plus docetaxel (75 mg/m²), or with doxorubicin (50 mg/m²), cyclophosphamide (600 mg/m²) and 5-fluorouracil (500 mg/m²) for their primary breast cancer. Their median age was 41 yr (range: 29-62) and all the tumors were larger than 3 cm in maximum diameter. SLNB was performed 3 min after periareolar injection of 1% isosulfan blue dye. All the patients underwent lymph node dissection at the level 1 and 2 axillary areas irrespective of their nodal status.
Results
A clinical response after neoadjuvant chemotherapy was observed in 46 patients (88%) and 11 (18.7%) patients had a complete pathologic response. Thirty-five patients (62.7%) underwent breast conserving surgery. The sentinel lymph node was identified in 96.6% and the median number of sentinel nodes was 3 (range: 1-6). The median number of dissected nodes was 14 (range: 11-47). Metastasis to the lymph node was observed in 56% of the patients. The sentinel lymph node was the only metastatic node in 12 patients. Three patients with a negative sentinel lymph node were confirmed to have metastasis to non-sentinel nodes after the final histologic examination (false negative rate: 9.1%). The overall accuracy of SLNB was 94.7%.
Figures and Tables
References
1. Miltenburg DM, Miller C, Karamlou TB, Brunicard FC. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res. 1999. 84:138–142.
2. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000. 18:3480–3486.
3. Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol. 2000. 24:1266–1272.
4. Nason KS, Anderson BO, Byrd DR, Dunnwald LK, Eary JF, Mankoff DA, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer. 2000. 89:2187–2194.
5. Haid A, Tausch C, Lang A, Lutz J, Fritzsche H, Peschina W, et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer. 2001. 92:1080–1084.
6. Fernandez A, Cortes M, Benito E, Azpeitia D, Prieto L, Moreno A, et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun. 2001. 22:361–366.
7. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol. 2002. 9:235–242.
8. Brady EW. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J. 2002. 8:97–100.
9. Miller AR, Thomason VE, Yeh IT, Alrahwan A, Sharkey FE, Stauffer J, et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol. 2002. 9:243–247.
10. Mamounas EP. Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am. 2003. 83:931–942.
11. Reitsamer R, Peintinger F, Rettenbacher L, Prokop E. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy. J Surg Oncol. 2003. 84:63–67.
12. Balch GC, Mithani SK, Richards KR, Beauchamp RD, Kelley MC. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol. 2003. 10:616–621.
13. Vigario A, Sapienza MT, Sampaio AP, Piato JR, Barros N, Barros A, et al. Primary chemotherapy effect in sentinel node detection in breast cancer. Clin Nucl Med. 2003. 28:553–557.
14. Piato JR, Barros AC, Pincerato KM, Sampaio AP, Pinotti JA. Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy: a pilot study. Eur J Surg Oncol. 2003. 29:118–120.
15. Schwartz GF, Meltzer AJ. Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J. 2003. 9:374–379.
16. Fisher B, Slack NH. Number of lymph nodes examined and prognosis of breast carcinoma. Surg Gynecol Obstet. 1970. 131:79–88.
17. Giuliano AE, Haigh PI, Brenan MB, Hansen NM, Kelly MC, Edwin WY, et al. Prospective observation study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel nodenegative breast cancer. J Clin Oncol. 2000. 188:2553–2559.
18. McMaster KM, Tuttle TM, Carlson DJ, Brown M, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection on multi-institutional practice when optimal technique is used. J Clin Oncol. 2000. 18:2560–2566.
19. Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000. 88:608–614.
20. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Metaanalysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006. 93:539–546.
21. Kim T, Agboola O, Lyman GH. Lymphatic mapping and sentinel lymph node sampling in breast cancer: a meta-analysis. 2002. Orlando, FL: 2002 ASCO Annual Meeting Proceedings;–256. available from: http://www.asco.org/portal/site/ASCO/menuitem.
22. Tausch C, Konstantiniuk P, Kugler F, Reitsamer R, Roka S, Haid A, et al. Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian sentinel node study group. Ann Surg Oncol. DOI;10:1245.
XML Download